Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...
Equities researchers at Wedbush lifted their Q4 2025 earnings per share estimates for shares of CarMax in a research note ...
Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing exchange-traded fund market. With more than 7K ETFs listed globally, collectively managing over $10T in ...
Palantir Technologies received a new Buy rating from Loop Capital and continued bullish support from Wedbush on Thursday, despite recent market concerns over potential U.S. defense budget cuts.
Wedbush will sponsor its own ETFs to provide clients and investors with cost-effective, transparent investment options designed to meet modern portfolio construction needs. “ETF creation is a logical ...
Wedbush Securities, a leading financial services and investment firm, is proud to announce the launch of fast and efficient services for easy-to-borrow, locates and hard-to-borrow securities.
Wedbush analysts believe Tesla (NASDAQ:TSLA) CEO Elon Musk's unsolicited $97.4 billion bid for OpenAI's controlling nonprofit is unlikely to succeed but is intended to slow down the company's ...
But now there is one analyst who’s again projecting upside: Wedbush’s Daniel Ives boosted his target price to $90 on Thursday morning. Palantir’s stock PLTR closed at $76.87 on Wednesday ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback